Ikena Oncology, Inc. and Inmagene Biopharmaceuticals have announced the appointment of Kristin Yarema, Ph.D., as the Chief Executive Officer of their newly merged company, ImageneBio, Inc. The merger is expected to close by the end of July 2025. Dr. Yarema brings extensive leadership experience in human therapeutics, having previously served as CEO of Poseida Therapeutics, Inc. The combined company will focus on developing treatments for autoimmune and inflammatory diseases and will trade on Nasdaq under the ticker symbol "IMA".
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ikena Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9499194-en) on July 23, 2025, and is solely responsible for the information contained therein.